Ethyl 2,4-dihydroxy-6-methyl-3-pyridinecarboxylate:Exports & Compliance White Paper 2026

I. Executive Summary

Ethyl 2,4-dihydroxy-6-methylnicotinate (CAS 70254-52-3; C9H11NO4, molecular weight 197.19) is the ethyl ester of a dihydroxymethylpyridine carboxylic acid: a substituted pyridine bearing two hydroxyl groups, a methyl group and an ester on a six-membered heteroaromatic ring. Despite the "dihydroxy" name, the molecule belongs to the hydroxypyridone family and behaves as a tautomeric system rather than as a simple phenol, which is the single most important fact for anyone specifying, storing or alkylating it. Commercial material is a high-melting, poorly water-soluble crystalline solid, commonly reported to melt above 200 degrees Celsius and often with decomposition, supplied as an off-white to pale-beige powder.

Supply is concentrated among heterocyclic custom-synthesis specialists in China and India, with a smaller European tier serving R&D and captive campaigns and with North American and Japanese buyers importing for pharmaceutical and agrochemical development. Buyers qualify on tautomer-related assay basis, regioisomer content, residual solvent and metal content, and they care about colour because metal chelation and oxidation both darken the material. Price is secondary to reproducibility: a dihydroxynicotinate whose tautomer or isomer ratio drifts changes alkylation regiochemistry downstream.

The 2026 regulatory position is unusually simple but frequently mishandled in buyer questionnaires. This molecule contains no carbon-fluorine bond at all: no CF3, no CF2 and no aryl fluoride. It is therefore outside the OECD perfluoroalkyl core definition by structure, outside the principal scope of the EU universal PFAS restriction proposal and of the PFOA and PFHxA restrictions, and it raises no trifluoroacetic-acid degradation question because it carries no fluorine to degrade. It is nevertheless routinely captured by brand and buyer PFAS questionnaires and by TSCA section 8(a)(7) reporting scoping, which typically require a documented negative declaration rather than a fluorine dossier.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule's behaviour follows from the 2,4-dihydroxypyridine motif, which exists in tautomeric equilibrium with the corresponding 4-hydroxy-2-pyridone form. Which tautomer dominates depends on solvent, pH, temperature and solid-state packing, and the two forms present different nucleophilic sites: the hydroxy form offers two oxygen nucleophiles and one ring nitrogen, while the pyridone form shifts reactivity toward nitrogen and changes the acidity of each site. That is why this intermediate is prized for regioselective elaboration and why its specification must be written by someone who understands the equilibrium.

• Pyridone tautomerism and its effect on assay: Because HPLC, titration and NMR respond differently to the hydroxy and pyridone forms, and because solid-state form can differ from solution form, a supplier must declare the analytical basis of the assay and state whether a specific tautomer or the tautomeric sum is being reported. Without that declaration, two laboratories can disagree on identical material.
• Alkylation regiochemistry and chelation: Dihydroxypyridines are bidentate chelators, so trace iron, copper and other transition metals both darken the solid and perturb alkylation outcomes. Process developers therefore control metal ingress from equipment and water and select O- versus N-alkylation conditions deliberately, because the tautomer equilibrium sets which site reacts first.

2.2 Synthesis and Manufacturing Technologies

Industrial material is made by constructing the pyridine ring rather than by functionalising a preformed one, using cyclocondensation chemistry in which a beta-ketoester component and a nitrogen-containing component such as an amidine, enamine or ammonia-equivalent are brought together, with the ester substituent carried through into the 3-position. The engineering challenges are regioisomer control, colour control and the avoidance of conditions that hydrolyse or decarboxylate the ester.

• Cyclocondensation route class: The route condenses a beta-ketoester-derived component with an amidine or enamine partner under basic or acid-catalysed conditions, closing the ring and installing the hydroxyl and methyl substituents in one sequence. Critical controls are the order of addition, the base strength, water content and the exotherm, because each moves the regioisomer ratio and the level of decarboxylated or hydrolysed by-product.
• Ester integrity, isolation and finishing: The ethyl ester is vulnerable to hydrolysis under strongly basic or acidic aqueous conditions and to decarboxylation once hydrolysed, so pH and temperature must be held inside a validated window and drying must avoid prolonged heat. Isolation is typically by controlled crystallisation with a defined polymorph and particle-size target, followed by low-temperature drying and milling under inert atmosphere to hold colour specification.

2.3 Core Application Matrix

• Pharmaceutical heterocyclic intermediates: The dihydroxynicotinate scaffold is elaborated by regioselective alkylation and by conversion of the hydroxyls into leaving groups, giving substituted pyridines and pyridones used across kinase, antiviral and anti-inflammatory discovery programmes. Customers buy on regioisomer documentation and on metal-content control.
• Agrochemical intermediate programmes: Substituted hydroxypyridines and pyridones appear in herbicide and insecticide discovery, where the chelating hydroxyl pattern and the ester handle allow rapid analogue generation. Buyers here prioritise supply security and specification stability across multi-year campaigns.
• CDMO custom synthesis and RUO campaigns: Custom-synthesis partners supply the material as an advanced intermediate under ICH Q7 and Q11, offering route development, analytical method development and validation, polymorph screening and tech transfer, typically starting at research-use-only or development grade.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is driven by heterocyclic discovery throughput rather than by a single commercial molecule: hydroxypyridine and pyridone motifs are standard scaffolds in kinase and antiviral chemistry, and the ester handle lets programmes generate analogues quickly. Demand is therefore lumpy, tied to individual development programmes, and sensitive to the funding cycle in small and mid-sized pharma. Because the molecule contains no fluorine, it is unaffected by fluorinated-substance restriction trends, which increasingly helps buyers simplifying their chemical inventory.

3.2 Capacity Distribution and Export Flows

Capacity sits with heterocyclic custom-synthesis specialists rather than with commodity producers. China dominates merchant supply through fine-chemical parks in Jiangsu, Shandong, Zhejiang and Hebei that host multi-purpose plants with crystallisation and drying capability. India supplies both merchant and captive material through Hyderabad, Ahmedabad and Mumbai clusters with strong analytical and regulatory documentation practice. Europe retains R&D-scale and captive capacity in Germany, Switzerland, Italy and the United Kingdom, focused on early-phase and high-value campaigns. Export flows run overwhelmingly from China and India to European, North American and Japanese customers.

3.3 Market Bifurcation and Pricing Dynamics

Two tiers coexist. Development and technical grade at 97 to 98 percent, supplied with a declared assay basis and a short impurity list, trades on heterocyclic-building-block margins and is quoted per kilogram rather than per tonne. Qualified GMP-aligned material at 99 percent plus, with validated methods, polymorph control, ICH Q3D elemental assessment and DMF or open-part support, commands a substantial premium and is sold on audit outcome. Since 2024 the gap has widened as analytical and documentation expectations rose while generic heterocyclic capacity expanded.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

This is a non-fluorinated heterocyclic intermediate, so the regulatory load is conventional: a correct GHS classification, a destination-language SDS, a tonnage-appropriate REACH position for the EU and a correct TSCA inventory position for the United States, plus pharmaceutical-sector expectations when the material feeds a regulated active substance. The complication is questionnaire-driven rather than legal: fluorine and PFAS declaration forms are sent to all intermediate suppliers regardless of chemistry, and they must be answered with evidence rather than ignored. It is not an approved drug substance and is supplied as an industrial or research-use-only intermediate.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and CLP classification: EU access requires tonnage-appropriate registration held by the importer or an only representative, CLP notification based on the substance's own hazard data, and a destination-language SDS with exposure scenarios where applicable. Downstream users need exposure-scenario support covering powder handling, charging and dust control, which is the realistic exposure route for a high-melting crystalline solid.
• PFAS adjacency and the negative declaration: This molecule contains no carbon-fluorine bond: no CF3, no CF2 and no aryl fluoride. It is structurally outside the OECD perfluoroalkyl core definition, outside the principal scope of the EU universal PFAS restriction proposal and of the PFOA and PFHxA restrictions, and it raises no trifluoroacetic-acid degradation question because there is no fluorine to degrade. Buyer questionnaires still ask, so the compliant response is a signed fluorine-free declaration supported by structural statement, raw-material declarations from fluoropolymer-free process contact where claimed, and a statement of no intentional fluorine input.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory and section 8(a)(7) PFAS scoping: US import requires a correct TSCA active inventory designation and a documented assessment of whether fluorinated-substance reporting reaches the material. Because the structural scoping definitions turn on the presence of fluorinated carbon moieties, the correct outcome for this substance is a documented negative determination, recorded with the structural reasoning and retained for the relevant period.
• ICH expectations and GMP audit readiness: Where material feeds a regulated active substance, buyers expect ICH Q7-aligned GMP at the registered starting-material step, an ICH Q11 development narrative covering tautomer and regioisomer control, ICH Q3D elemental assessment, ICH Q3C residual-solvent control and DMF or CEP-supporting documentation with audit readiness. Nothing here is a therapeutic claim: this intermediate has no approved indication of its own.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental pressure on heterocyclic custom synthesis concentrates on solvent load, aqueous waste from quench and crystallisation, and energy for drying and solvent recovery. Buyers increasingly request quantified evidence rather than assurances, so suppliers holding solvent-recovery rates, emissions per kilogram and verified waste routes clear procurement screens that price alone cannot.

5.1 Carbon Footprint and Circular Economy

Most cradle-to-gate footprint sits in solvent manufacture and in energy for reaction heating, solvent recovery by distillation and low-temperature drying, rather than in the carbon skeleton itself. Levers are solvent selection guided by green-chemistry criteria, solvent recovery and reuse, heat integration across batch operations, and mother-liquor rework that raises overall yield. Scope 1 and Scope 2 accounting is standard in questionnaires and Scope 3 upstream data is increasingly requested.

5.2 Sustainable Sourcing and Traceability

Buyers should require current ISO 9001 and ISO 14001 certificates, third-party environmental and, where applicable, GMP audit reports, the key raw-material sources including the beta-ketoester and nitrogen-component suppliers, and an account of solvent and aqueous waste destination including licensed treatment or recovery. Chain-of-custody documents should follow each lot: batch number, certificate of analysis, and a signed fluorine-free declaration answering PFAS questionnaires without ambiguity.

VI. Supply Chain Resilience and Export Logistics

A high-melting crystalline solid is generally easier to ship than a corrosive liquid, but it is not trouble-free: the material is light- and oxygen-sensitive over long storage, darkens with metal contact, and its flow and dissolution behaviour depend on particle size and polymorph. Logistics must therefore protect colour, moisture content and physical form rather than temperature alone, and dust control must be designed into packing and charging.

6.1 Packaging Standards and Moisture/Contamination Control

• Container material and closure integrity: Pack in polyethylene-lined fibre drums or HDPE drums with low-metal-contact liners, sealed with moisture-barrier bags and desiccant where the water specification demands it, and avoid metal scoops or unlined steel contact that can seed colour. For development quantities, amber glass with inert headspace is standard, and light protection during storage should be stated on the label.
• Analytical release and stability monitoring: Release on HPLC assay with declared tautomer basis, related substances, residual solvent, water, heavy metals and colour by a defined method. Retained samples under a documented stability protocol with assay, water and colour trended at defined intervals let the supplier defend a retest period, and give the buyer evidence that a change is packaging-related rather than chemical.

6.2 Dangerous Goods Identification and Transit Protocols

Many lots of this type are not classified as dangerous goods for transport, but that outcome must be confirmed against the substance's own classification and the certified data for the specific formulation rather than assumed, since some heterocyclic powders carry irritant or toxic classifications. Where the material is unregulated, shipments still require UN-specification-equivalent industrial packaging, tamper-evident seals, dust-tight closures and complete documentation. Transport follows ADR, the IMDG Code and IATA DGR where a classification applies, with moisture-protected stowage and no cold-chain requirement under normal conditions.

VII. Enterprise Global Expansion Strategy Guide

Three priorities decide who wins: tautomer and regioisomer documentation that survives a customer audit, a fluorine-free declaration that closes PFAS questionnaires quickly, and physical-form control that protects colour and performance.

1. Specify the tautomer and the isomer: Declare the analytical basis of the assay, set a regioisomer limit and validate HPLC and NMR methods accordingly, then hold both within change control. This discipline removes the commonest source of disputes on dihydroxypyridine intermediates.
2. Answer the fluorine question in writing: Issue a signed fluorine-free declaration with the structural statement, note the absence of any trifluoroacetic-acid degradation pathway, and record the documented negative determination under TSCA section 8(a)(7) scoping, so buyer questionnaires close in one exchange.
3. Offer development and GMP streams: Run RUO and development-grade campaigns with analytical method development under ICH Q7 and Q11, then step into GMP with validated methods, polymorph control, ICH Q3D assessment, DMF or open-part support and regional buffer stock in Europe or India.

VIII. Conclusion

Ethyl 2,4-dihydroxy-6-methylnicotinate is a specialist heterocyclic building block whose value lies in regioselective elaboration rather than in volume. Its 2026 risk profile is dominated by definition and documentation rather than by synthesis capability: tautomer-aware assay, regioisomer limits, polymorph and colour control, ICH Q3C and Q3D evidence, REACH and TSCA position, and a signed fluorine-free declaration that closes PFAS questionnaires without ambiguity.

For buyers the recommendation is to qualify on the full analytical package, to audit metal-contact and drying controls, to require thermal and polymorph data before approving any isolation step, and to contract around documented campaigns with dual sourcing across China and India. That buys reproducibility, which is the specification that matters most for a tautomeric, chelating intermediate.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Ethyl 2,4-dihydroxy-6-methylnicotinate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Ethyl 2,4-dihydroxy-6-methylnicotinate supply chain:

• China heterocyclic custom-synthesis base: The largest merchant capacity, in Jiangsu, Shandong, Zhejiang and Hebei fine-chemical parks using multi-purpose plants with cyclocondensation, crystallisation and low-temperature drying capability, exporting through Shanghai and Ningbo with ISO 9001 and ISO 14001 certification and increasingly GMP-aligned documentation.
• India CDMO and API-intermediate hubs: Hyderabad, Ahmedabad and Mumbai clusters combine heterocyclic route development with strong analytical capability, offering method validation, polymorph screening, impurity profiling and tech transfer under ICH Q7-aligned systems, and serving Western innovator and generic programmes.
• European and North American compliance-led ecosystem: Germany, Switzerland, Italy and the United Kingdom host R&D-scale and captive heterocyclic capacity with the strongest REACH, CLP and GMP documentation practice, plus contract analytical laboratories and DMF and CEP consultancies.